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ABSTRACT  The interrelationship  of several  physiological  receptors which in-
fluence the hydroosmotic  response  of the toad urinary bladder was studied  em-
ploying neurohypophyseal  peptides,  prostaglandin  E1,  theophylline,  and  cyclic
nucleotides.  The binding property of agonists (pD2), synergists (pS2), competitive
antagonists  (pA2 ),  and  noncompetitive  antagonists  (pD2')  was determined  after
a  suitable  methodology  had  been  developed.  A  series  of  neurohypophyseal
peptides  was  examined  in detail  for their catalytic  activity.  It was  found  that
the  replacement  of the hydroxy radical of the  tyrosine residue in oxytocin  by a
methoxy  and  then  by  an  ethoxy  radical  led  to  a  progressive  decline  in  the
catalytic  activity  of the hormone-corresponding  to  a  change from  agonist  to
partial  agonist  to  competitive  antagonist.  [4-Leucine]-mesotocin  behaved
as  a  competitive  antagonist  of oxytocin.  Prostaglandin  E1 (PGE1)  was found
to be  a noncompetitive  inhibitor of neurohypophyseal  peptides  and  theophyl-
line; whereas the maximal hydroosmotic response of the bladder to [2-0-methyl-
tyrosine]-oxytocin  and  theophylline  was  greatly  depressed  by  PGE1,  the
response to saturating concentrations  of oxytocin was only slightly diminished-
a finding  which reveals  a "receptor  reserve"  for  oxytocin.  Saturating  concen-
trations  of  [2-0-ethyltyrosine]-oxytocin,  inactive  per  se,  potentiate  theo-
phylline-disclosing  a  "threshold  phenomenon"  for  the mediation  of neuro-
hypophyseal  hormone  action.  It  is  concluded  that neurohypophyseal  peptides
are  capable  of  producing  graded  effects  on  adenyl  cyclase  both  below  and
above  the  range  of  enzyme  activity  which  evokes  graded  changes  in  mem-
brane permeability.
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INTRODUCTION
Sutherland  and  associates  (35,  43)  have  shown that a number  of hormones
with diverse physiological  functions  operate at their target cells  through the
adenyl  cyclase-3',5'-AMP  system.  We  have  been  interested  in  the  hydro-
osmotic  response  of the toad  bladder  to neurohypophyseal  hormones where
the primary  hormone-receptor  interaction  appears  to be  translated  into  an
alteration  in the rate of formation of cyclic AMP from ATP (33),  and where
the cyclic  nucleotide in turn triggers through one or more intermediate steps
the final  effector  machinery  of the  cell.  In this  study we  have  investigated
neurohypophyseal  peptides,  theophylline,  and  prostaglandin  E1 (PGE1),  as
modulators  of the intracellular  level  of cyclic AMP in order to  gain insight
into the question of whether each increment of adenyl cyclase activity can be
translated  into an increment of hydroosmotic activity,  or whether steps sub-
sequent  to adenyl  cyclase  activation are limiting  in the over-all  response  of
the tissue to hormone.  In order to characterize  the interaction  of these com-
pounds with their receptors,  we have drawn on the approach which has been
applied  to drug-receptor  interactions  (3,  20, 45).
MATERIALS  AND  METHODS
Symbols
[A],  concentration  of  agonist,  i.e.
a compound capable of evoking
a hydroosmotic response  in the
toad  urinary bladder
[B],  concentration  of a competitive
antagonist of A
[B'],  concentration  of  a  noncom-
petitive antagonist  or a  syner-
gist of A
E,  maximal  hydroosmotic  re-
sponse  capacity  of  the  target
tissue
Ero,  half-maximal  hydroosmotic  re-
sponse
EA,  hydroosmotic  response  to  a
given  concentration  of A
EAB,  hydroosmotic  response  to A  in
the presence of B
EA,,  maximal  hydroosmotic  re-
sponse reached  with saturating
concentrations  of A
EAB,,,  hydroosmotic  response  to  a
given concentration  of A in the
presence  of saturating concen-
trations  of  a  synergist  B'
h.,  (EAB,  - EA)/Em,  maximal
synergistic  effect of a synergist,
B',  on  the  response  to  A  ex-
pressed  as  a  fraction  of  the
maximal  response of which the
target tissue is capable
EAm,B,,  hydroosmotic  response  to satu-
rating  concentrations  of  A  in
the presence  of saturating con-
centrations  of  noncompetitive
antagonist B'
h.',  (EA  - EAtB,.)/Em,  maximal
antagonistic effect of a noncom-
petitive inhibitor, B', on the re-
sponse to A  expressed as a frac-
tion  of  the  maximal  response
of  which  the  target  tissue  is
capable
[A]50,  concentration  of A  which  will
evoke an Es0 response
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[A]50B,  concentration  of A  which  will
evoke  an  E 0 response  in  the
presence  of a given  concentra-
tion of B
[B]50,  the  concentration  of B  which
establishes  the  ratio  [A]50B/
[A], 0 =  2
[B']60,  the  concentration  of B'  which
elicits  a  half-maximal  syner-
gistic  or  noncompetitive  in-
hibitory effect
KA,  KB,  dissociation  constants  for  the
complexes  of A  or B and  their
receptors
pD2,  -log  [A]50,  where  A  is  an
agonist
pA2,  -log  [B]50,  where  B  is  a  com-
petitive antagonist
pS2,  -log [B']50,  where  B'  is  a
synergist
pD2',  -log  [B']50, where B' is a non-
competitive antagonist
Reagents and Procedures  for Measuring Water Permeability of the Toad Bladder
Toads,  Bufo  marinus L.  (National  Reagents  Inc., Bridgeport, Conn.), weighing  from
150-250 g were kept on moist peat moss.  Specimens  of both  sexes  were  pithed  and
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FIGURE I.  Structure of oxytocin. Numbers indicate the position of the individual amino
acid residues.
their urinary bladders placed in Ringer fluid of the following composition  (mM):  NaCI,
110; KC1, 3; CaC12,  1; MgCl 2,  1; NaHC03,  3; dextrose,  5.5;  tris(hydroxymethyl)am-
inomethane  hydrochloride  (Trizma),® 10; pH = 8.4; tonicity,  245  t  3 milliosmols
per liter.
The following  compounds were  employed  in  this study:  [8-arginine]-vasopressin
(15),  oxytocin  (16,  17)  (Fig.  1),  crystalline  [1-/-mercaptopropionic  acid]-oxytocin
(deamino-oxytocin)  (19),  [5-ornithine]-oxytocin  (22),  [2-0-methyltyrosine]-oxytocin
(25,  27),  [2-O-ethyltyrosine]-oxytocin  (46),  [4-leucine]-mesotocin,  [4-leucine-8-
isoleucine]-oxytocin  (36), prostaglandin  E1 (PGE 1)  (Upjohn Co., Kalamazoo,  Mich.),
cyclic 3' ,5'-adenosine  monophosphate  (cyclic AMP),  N0-2'-O-dibutyryl cyclic  3',5'-
adenosine  monophosphate  (Schwarz  Bio  Research,  Inc.,  Orangeburg,  N.Y.),  and
theophylline. The neurohypophyseal hormones and synthetic analogues were checked
for  their physical  properties  (specific  optical  rotation),  purity  (thin-layer  chroma-
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tography),  and biological  activity  (fowl  vasodepressor  assay  [29])  just prior to  use;
the data obtained agreed  with those reported  for these  compounds  in the references
cited  above.  For estimating  the permeability  to water  of the toad  urinary  bladder
the sac preparation  of Bentley  (9)  was employed with minor modifications.  In brief,
hemibladders of comparable sizes are tied to the end of glass tubes so that the mucosa
forms the inside of a sac which is filled with 7 ml of dilute Ringer fluid (50 milliosmols
per  liter).  Four  or  more  bladders  are  suspended  in  a  106 ml  bath of full strength
Ringer fluid stirred with an air jet. After a 2 hr period of incubation in this solution,
bladders are transferred to the challenge  bath. The rate at which water escapes  from
the mucosal  fluid through the bladder wall  is monitored  by removing the sac prepa-
ration from the serosal bath and weighing it at intervals of 30 min. After each weigh-
ing,  bladders  are  emptied  and  filled  with fresh dilute  Ringer fluid,  reweighed  im-
mediately,  and placed  into  a fresh  bath.
General Protocol for Determination of the Eso
The  half-maximal  hydroosmotic  response  of a hemibladder  to  a  given  agonist  (or
an  agonist in combination  with  an inhibitor  or synergist)  is determined  in  the fol-
lowing  manner:  the  hemibladder  is  exposed  for the  first 30  min  interval  to  a  low
concentration of agonist  (a concentration  which will evoke  a 10-40 % response),  then
for a second  30  min interval to  twice  that concentration,  and finally for a third 30
min interval to a concentration above that known to be needed for a maximal effect.
The rate  of weight  loss  of the  bladder following  the two  submaximal  challenges  is
expressed  as  a  fraction  of the  maximal  response;  and  the concentration  of agonist
corresponding  to the half-maximal  response,  [A]50 or [A]5B, is determined  by inter-
polation  on  a  logarithmic  scale  between  the  two  submaximal  response  values  as
illustrated  in  Fig.  2.  In several  experiments  the response  of the  hemibladder  was
tested at more than three concentrations  of agonist.  Bladders in which the initial low
concentration  of agonist evoked  a response in excess of 50 % were  discarded.
Potencies of Agonists (PD 2)
The interaction of a hormone  (A)  with its receptor (R) can be represented  by  models
based  on the  mass action  law or the Langmuir adsorption  isotherm which  describe
the probability  of a given number of molecules of A interacting with a given number
of molecules  of R:
[A] +  [R]  [AR];  = K,
k2  1
The  interaction  of A  with R is  assumed  to result  in a  stimulus  and,  according  to
current  pharmacological  concepts  concerning  occupancy  of  receptor  sites  (3,  20,
45),  the stimulus,  SA,  generated  as a consequence of an agonist,  A,  interacting with
its specific receptor can  be quantitated as follows:
SA/Sm  =1  (44)
Stimulation  expressed  as  a  fraction  of the  maximal  possible  stimulus  (SA/S,)  is
dependent upon  the concentration  of compound  A,  the dissociation  constant of the254  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  · VOLUME  56  · 1970
agonist  receptor  complex  (Ka),  and  the  proportionality  constant  (a),  relating  the
degree  of receptor occupation  by  A  to the degree  of stimulus  formation.  The  con-
stant,  ao, is  referred  to  as intrinsic  activity  of A  (2).  The equation  given  above  as-
sumes that the agonist, A,  reacts  with  a single  type of receptor  or  a set of receptors
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FIGURE  2.  Method  for  determining  [J]5 O and  [A]50B  values.  The  hydroosmotic  re-
sponses  of  three  sets  of  contralateral  hemibladders  to  a  given  concentration  of  de-
amino-oxytocin  alone  (-  e)  and  a  deamino-oxytocin-[2-0-ethyltyrosine]-oxy-
tocin  mixture  (e---e).  Deamino-oxytocin  alone  is  employed  at  two  levels  of
concentration,  the  lower  concentration  selected  to  evoke  less  than  the  half-maximal
response (Eso) of the bladder and  the higher concentration  being twice that of the lower.
The response  is plotted  against  the  logarithm  of the  deamino-oxytocin  concentration.
The  concentration  of deamino-oxytocin  which  evokes  a  half-maximal  response  of  one
hemibladder (bladder a, b,  or c)  is read  off the  abscissa as the [Ajo value. The concen-
tration  of deamino-oxytocin  which,  in  the presence  of inhibitor,  evokes  a half-maximal
response  in the  contralateral  hemibladder  (bladder  a',  b',  or  c',  respectively)  is  read
off the  abscissa  as the  [A]6soB  value.
with similar  KA  values.  The  applicability  of this  assumption  to the  receptors  asso-
ciated with the hydroosmotic response of the toad bladder  is supported  by a detailed
analysis  of  the  dose-response  relationships  of several  neurohypophyseal  hormones
and synthetic  analogues reported  previously  (18).
When  the relationship  between  stimulus and  final effect  is linear,  the  concentra-P.  EGGENA ET AL.  Neurohypophyseal Peptide Action
tration of agonist  which  will evoke  a half-maximal  response  ([A]50)  equals KA  and
the binding constant  (affinity)  of A  for  its receptor  is  given by  /KA.  The negative
logarithm of the concentration  of agonist  that will evoke a half-maximal  effect  is re-
ferred  to  as  its pD2 value  (5,  28).  With  these  considerations  in  mind  we  derived
pD2 values  for a number  of neurohypophyseal  peptides on  the toad  bladder.  How-
ever,  it will be shown in this paper that the bladder exhibits threshold  and receptor-
reserve  phenomena,  so that,  strictly speaking,  a 50 % hydroosmotic response  usually
does not imply 50 % receptor occupation by the nonapeptide.  Only when the number
of receptor sites below threshold equals the receptor sites that constitute the receptor-
reserve  will  [A] 5 0 equal K--an assumption which  cannot  be made  a priori for the
interaction  of a given agonist with  the toad bladder.  Therefore,  when the receptor-
reserve  exceeds the subthreshold,  the  KA  of an  agonist  will  be  underestimated,  al-
though the resultant error in the pD2 value is minimized  by the fact that the slopes of
dose-response  curves are steep; i.e.,  a large change in response  (ordinate)  is associated
with a relatively small change in the concentration  of agonist (abscissa).
Since  bladders  from  different  toads  vary  considerably  in  their  sensitivity  to  a
given challenge,  it is advisable  to compare  the concentration  of an unknown  agonist
which will  evoke  a half-maximal  hydroosmotic  response,  i.e.  its [A] 50 value,  in one
hemibladder to the concentration  of a standard which will evoke  the same  response
in  the  contralateral  hemibladder  of  the same  toad.  We have  employed  crystalline
deamino-oxytocin  as  a reference  standard  (18)  and  have  found  the  [A] 5 0 value  for
this standard  to be 5.53  X  10-9  M z-  0.34  (SEM). 1 The [A] 5 0 value for the  unknown
substance  is then normalized  in the following manner:
Normalized  [A]50 unknown  = 5.53  X  10- 9 M X  [A]0 unknown
[A]50 deamino-oxytocin
The pD2 value of the  unknown agonist is  then equal to the  negative logarithm  of the
normalized  [A] 5 s.
Potencies of Competitive Antagonists (pA2)
When an antagonist B competes with an agonist A for the same  receptor system,  the
dose-response  curve  for  A will  be  shifted  in a parallel  manner progressively  to  the
right along the log-dose axis as the concentration  of B is increased.  Since the antago-
nism  is surmountable,  increasing  concentrations  of agonist will  result  in a response.
The magnitude  (7)  by which the dose-response  curve  is shifted at E5 0 is given by:
[A]OB  1 +  [B]
[A]50 KB
The fraction  [A]5oB/[A]5o denotes the extent by  which the competitive  antagonist B
displaces  the midpoint of the concentration-response  curve  of agonist A  to the right
(see  Fig.  3).  The  concentration  of competitive  inhibitor  which  produces  a  twofold
shift of the dose-response  curve  of the  agonist to higher concentrations  is related  to
the dissociation constant of the antagonist-receptor complex  ([B]  =  [B]50 =  KB).  The
1 This value was obtained from dose-response curves on 86 toads, both sexes,  including studies carried
out in all seasons.
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negative  logarithm of [B]50 has  been referred  to as pA 2 by  Schild  (40).  The parallel
shift of the dose-response curve is a consequence of a parallel shift in the dose-stimulus
curve;  therefore,  threshold  or reserve  phenomena  do  not  influence  this  displace-
ment (4).
TABLE  I
DETERMINATION  OF THE pAD  VALUE
FOR  [2-O-ETHYLTYROSINE]  -OXYTOCIN
Agonist:  Deamino-oxytocin,  A
Antagonist:  [2-O-Ethyltyrosine]-oxytocin,  B
[A]soB
Toad No.  [A10]  X  10-m  [A]sOB*  X  10-~m  [A]ao
when
[B]  =  1.0  X  10-7M
1  7.7  10.5  1.36
2  8.2  11.2  1.36
3  6.4  10.2  1.59
4  7.2  9.2  1.27
5  6.8  12.2  1.79
6  7.6  12.2  1.60
7  6.8  12.8  1.88
8  6.8  11.0  1.61
Average  1.56  4-  0.08
when
[B]  =  2.5  X  10-
7
M
9  8.9  22.3  2.51
10  6.6  15.6  2.36
11  6.6  16.5  2.50
12  7.6  18.5  2.43
13  8.0  19.6  2.45
14  5.8  14.5  2.50
15  5.6  13.6  2.43
16  9.8  26.8  2.73
Average  2.49  0.04
[A]o  =  7.27  X  10-gi  4- 0.27.  [B]t, =  1.55  X  10-
7 M 4- 0.10:.  pAD  =  6.81  4  0.03.§
* Values  of  [A]6O  and  [A]oB  determined  graphically  as  illustrated  in  Fig.  2.
[A]Hn
: When  [-A  =  2.00;  B]  =  [B]t  =  1.55  X  10
- 7 M -4- 0.10  (SEM  measured  graphically  as de-
[Als
scribed in text).
§pA 2 =  -log 1.55  X  10
- 7 M =  6.81  0.03.
With respect to the hydroosmotic activity in the toad bladder  the affinity constant
of a  competitive  inhibitor  is  best  evaluated  by  determining  the  [A]50 value  of the
reference  agonist in one hemibladder  and an [A] SB value for any given concentration
of antagonist  B  in  the  contralateral  hemibladder  (see  Fig.  2).  This  procedure  is
repeated  on fresh hemibladders with  a different  concentration  of B. The concentra-
tion  of B  is varied  in such  a manner  that at least  one  value  for the ratio,  [A]50B/
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[A]50,  is obtained which  is greater and  one  value which  is less  than 2.  The concen-
tration of B which produces a twofold shift of the dose-response  curve, [B]50, is deter-
mined by plotting the ratio of [A]5 0B/[A]5o on the ordinate  vs.  the log  of [B] on the
abscissa  and reading  off the  value  of [B]  corresponding  to  [A]5oB/[A]5  =  2.  The
standard  error for the mean  [B]50  value  was  measured  graphically  by  (a)  drawing
a line  parallel to the  abscissa  through the  point on  the ordinate  corresponding  to
[A]5B/[A]5o = 2  and  (b)  connecting  upper and  lower limits respectively  of the  SEM
values for fractions  [A]50B/[A]5o. The limits  of the SEM for [B]50 are then  given by the
points of intersection  of curves  (a) and  (b), values which are read off on the abscissa.
The procedure  for measuring pA2 values is  illustrated in Table I with [2-0-ethyl-
tyrosine]-oxytocin,  which competitively inhibits the hydroosmotic action of deamino-
oxytocin.  Unlike  the pD2 values for different  agonists,  the pA2 values  for different
antagonists  have  not  been  normalized,  since  both  hemibladders  of  the  toad  are
required for determining  the pA2 value of a given antagonist.  However,  [A]50B  values
for  different  concentrations  of B have  been  normalized  with respect  to  the  [A]50
value of a given agonist (see  Fig. 3)  as follows:2
[A]50 
Potencies of Synergists (pS')  and Noncompetitive Antagonists (pD2')
A  stimulus  generated  as  a consequence  of  an  agonist interacting  with  its primary
receptor may be amplified  or dampened  by the action  of substances  influencing  any
step  other than the initial agonist-receptor  interaction.  It  is useful to define the po-
tency  of such substances,  synergist  or noncompetitive  antagonist,  by the concentra-
tion which will evoke  a half-maximal  synergistic  or  antagonistic  effect,  and then  to
express that concentration in terms of the negative logarithm.
The  following protocol  was  employed  for the  evaluation  of synergists:  a control
set of hemibladders  is challenged  at 30 min  intervals with three or four successively
increasing  concentrations  of agonist  alone.  The  experimental  set  of hemibladders
from the same  toads is also  challenged with increasing concentrations  of agonist, but
in the presence of a fixed concentration  of synergist. For each concentration of agonist
to be tested fresh mucosal  and serosal baths are  used; for each level of synergist to be
tested,  fresh hemibladders  are employed  for both the control  and the experimental
sets.  The concentration  of synergist  is raised  in separate experiments  until a further
increase in concentration will not evoke a further increase in response. The maximal
synergistic effect,  (h,), is  given by the vertical3 distance between the steep portion  of
2 For  example  with the  agonist  deamino-oxytocin  ([A]50  =  7.27  X  10-  M 4  0.27)  and the  an-
tagonist [2-O-ethyltyrosine]-oxytocin  with toad  1 in Table  I:
10.5  X  10-g M Normalized  [A]0B  =  7.27 X  10
-9 M  X  =  9.89  X  10-9 M.
7.7 X  10-9 M
3  We  have  chosen  in this study  to evaluate  the  synergistic  effect  by measuring  the vertical  rather
than the horizontal  distance  between  concentration-response  curves,  because  we have  interpreted
the  interaction  between  adenyl  cyclase  activators  and  phosphodiesterase  inhibitors  in terms  of a
virtual increase  in intrinsic activity  rather than  in  affinity.
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the  log-dose response  curve of the reference  agonist A  alone  and that of the agonist
in the presence  of saturating concentrations  of synergist evaluated in matched  hemi-
bladders. The  hm value  depicted in Fig. 4 represents the average  of several  hm  values
each derived  from individual  pairs of matched  hemibladders.  The concentration  of
synergist  that  will  yield  a  half-maximal  synergistic  effect,  h/2, is  determined  by
interpolation  between response  values just above and  below h,/2. We have referred
to  the  negative  logarithm  of  the  molar  concentration  of the  synergist  which  will
elicit a half-maximal  effect as its pS2 value;  i.e., pS2 =  -log[B']so.
The  concentration  of  a  noncompetitive  antagonist  which  will  produce  half-
maximal  inhibition  is determined  as  follows: The protocol  for obtaining  families  of
dose-response  curves  is  identical  to  that employed  for  the evaluation  of synergists.
The maximal effect of the  antagonist  is  most  accurately  measured  in  combination
with  a partial  agonist,  i.e.  an  agonist  which  is  incapable  of eliciting  the  maximal
hydroosmotic response of which the bladder is capable  (EAm/E  <  1.0); the maximal
antagonistic  effect,  l,,', is given  by the difference  in maximal  responses to saturating
concentrations  of partial agonist alone  and in  the  presence  of saturating concentra-
tions  of antagonist  as well  (see  Fig.  5 A  and B).  The negative  logarithm of the con-
centration  of  the noncompetitive  antagonist  for  half-maximal  inhibition  has  been
termed the pD2' value; i.e., pD2' =  -log  [B']5 0 (5).
RESULTS
Competitive  Antagonism  with  [2-O-Ethyltyrosine]-oxytocin  and  [4-Leucine]-
mesotocin
[2-O-Ethyltyrosine]-oxytocin and [4-leucine]-mesotocin  failed to increase  the
osmotic  flow  of water  across  the toad  bladder,  when  added  to  the  serosal
medium to give concentration  levels  as high as  10- 5 M. However,  both  these
agents  inhibited  the  hydroosmotic  action  of active  neurohypophyseal  prin-
ciples.  The  log  dose-response  curves  of  deamino-oxytocin,  [8-arginine]-
vasopressin,  [2-0-methyltyrosine]-oxytocin,  and  [5-ornithine]-oxytocin  were
shifted  to the right progressively  and in a parallel manner by increasing con-
centrations of [2-0-ethyltyrosine]-oxytocin.  This effect  of [2-O-ethyltyrosine]-
oxytocin  is  illustrated in Fig.  3,  where deamino-oxytocin  served  as the refer-
ence  agonist.  As  can  be  seen  in  Table  II,  we  selected  neurohypophyseal
peptide agonists with a wide spectrum of affinities,  ranging  in their pD2 values
from 4.92  0.04 for [5-ornithine]-oxytocin  to 9.40  i  0.07 for [8-arginine]-
vasopressin.  However,  the  affinity  of  the  antagonist  [2-O-ethyltyrosine]-
oxytocin  was  largely  independent  of  the  potency  of  the  agonists  as  mani-
fested  by  the  finding  that  the pA2 value  for  (2-O-ethyltyrosine]-oxytocin
varied  only  between  6.60  4  0.04  and  7.22  ±-  0.04  (Table  II).  Because  of
the  small amount  of  [4-leucine]-mesotocin  available,  its pA2 value  was only
studied with respect to one reference  agonist,  oxytocin,  and found to be 5.94
- 0.05.  The  inhibitory  action  of  both  antagonists  on  the  hydroosmotic
response  of the  bladder was reversible and specific for the neurohypophyseal
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FIGURE  3.  Inhibition  of  the hydroosmotic  response  of the  toad  bladder  to  deamino-
oxytocin  caused by increasing concentrations  of [2-0-ethyltyrosine]-oxytocin  [B]. Curve
a represents the response of the bladder in relation to the logarithm of the concentration
of deamino-oxytocin  [A]  in the absence  of inhibitor;  curves  b, c, d,  and e represent  the
response of the bladder to deamino-oxytocin in the presence of 1.0, 2.5,  5.0, and 20.0  X
10
- 7 M  [2-0-ethyltyrosine]-oxytocin,  respectively.  Curves  b,  c, d, and  e are normalized
with respect to the midpoint of curve  a and the midpoint of curves  b, c, d, and e is shifted
to the right by a factor  of:  1.56  4- 0.08  (SEM),  2.49  4- 0.04,  6.33  i  0.10,  and  10.90  4-
0.11,  respectively.  Each  curve  represents  the  average  response  of  eight  fresh  hemi-
bladders.
TABLE  II
COMPETITIVE  INHIBITION  OF  SOME
NEUROHYPOPHYSEAL  PEPTIDES  BY  [2-O-ETHYLTYROSINE]-OXYTOCIN
AND  [4-LEUCINE]-MESOTOCIN
pA2 of [2-0-Ethyltyrosine)-  pA2 of [4-Leucine]-
pD  of reference  agonist  oxytocin  mesotocin
Reference agonist  (SEM)  (:SM)  (:EM)
[8-Arginine]-vasopressin*  9.40  4- 0.07  6.66  i  0.05
Oxytocin*  8.63  0.02  6.85  4  0.03  5.94  0.05
Deamino-oxytocin  8.25  0.03  6.81  - 0.03
[2-O-Methyltyrosine]-oxy-  7.09  4- 0.05  7.22  4  0.04
tocin:
[5-Ornithine]-oxytocin§  4.92  +  0.04  6.60  4  0.04
Average  6.83  4  0.11
*  pD, values calculated  on  the basis of data reported  by Eggena et al.  (18).
: The pDa value of 7.09 corresponds  to an  [A]5 0 value of 1.23  X  10
- 7 M. The  [A]50 which  we  re-
ported  earlier  (18)  is superceded.
§ Data reported  by Havran  et al.  (22).
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hormonal  receptor because they did not diminish the  hydroosmotic  action  of
cyclic  AMP  and  theophylline;  indeed  the  effect  of theophylline  was  poten-
tiated  (see below).
Synergism  of  [2-O-Ethyltyrosine]-oxytocin and Theophylline
While  [2-O-ethyltyrosine]-oxytocin  competitively  antagonized  the action  of
neurohypophyseal  hormones,  this analogue was found to facilitate the perme-
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FiGURE  4.  Synergism of theophylline  and  [2-0-ethyltyrosine]-oxytocin.  The  log  dose-
response  curve for theophylline alone  (o  o)  is  compared  with the log  dose-response
curve for  theophylline  in the presence  of 5  X  10-8 M (o----- ),  1  X  10
- 7
M  (-----),
2.5  X  10- 7 M  (x-----x), and  I  X  10
- 6 M (-----  A) [2-0-ethyltyrosine]-oxytocin  (O-Et-
Oxy),  respectively.  The  synergistic  effect  of  maximal  concentrations  of  [2-0-ethyl-
tyrosine]-oxytocin  is  given  by  h,.  Each  curve  represents  an average  of six  or  more
experiments  on  fresh  hemibladders.  All curves  have  been  normalized  with  respect  to
the control  curve  (o-  o).  Standard  errors  (SEM)  are indicated  for mean  concentra-
tions of theophylline which will evoke E5 0 responses;  see text for sEM  of h,.
ability  response  of the bladder  to theophylline.  In  the presence  of increasing
concentrations  of [2-O-ethyltyrosine]-oxytocin (5.0  X  10- s to 2.5  X  10- 7 M)
the midpoint of the dose-response curve for theophylline was shifted to the left
along the  log-dose axis and  there was a  22%  increase  in maximum response
(Fig.  4).  A  further  increase  in  the  concentration  of  [2-O-ethyltyrosine]-oxy-
tocin to  1.0  X  10-6  M was without significant effect.  The maximal synergistic
effect, h,,  amounts  to  0.60  0.04  (SEM),  and  the  concentration  of  [2-0-
ethyltyrosine]-oxytocin  which  elicits  a  half-maximal  synergistic  effect  (i.e.
hm/2  =  0.30)  was determined  to be  1.0  X  10- 7 M; consequently,  its pS2 value
amounts to  7.00  t  0.05  (SEM).
I  I
i  ,
1a  /
i,  I
I  /  E
-o  0.0  M
i
/ ,/  hl  0---  I X 10-
7M
/I,  x----  2.5x10
7 M
h,--&  IxlO'Mo
260P. EGGENA  ET  AL.  Neurohypophyseal Peptide Action
Noncompetitive Antagonist: Prostaglandin  E1
In confirmation of the findings of others  (34)  PGE1 per se did not increase the
bladder permeability  to water when tested  in the serosal bath at concentra-
tions  as high as 2.86  X  10- 6M. PGE1 also proved to be a potent inhibitor of
the hydroosmotic  action of neurohypophyseal  peptides and theophylline,  but
only  minimally  influenced  the  action  of  dibutyryl  cyclic  AMP  (as  shown
in Fig.  5 D,  a  maximal  response  to  dibutyryl  cyclic  AMP  of 0.80  - 0.04
(SEM)
4 was  depressed  to  0.72  -t-  0.05  by  2.9  X  10- 7 M PGE1).  The  dose-
response  curves  of  both  theophylline  and  of  [2-O-methyltyrosine]-oxytocin
are  influenced  similarly by PGE1.
As shown in panel A of Fig.  5, the maximal response to the partial  agonist
[2-O-methyltyrosine]-oxytocin,  unlike  the  response  to  oxytocin,  is  progres-
sively  depressed from 0.88  ±- 0.03  (sEM)  to  a minimal value of 0.10  +  0.01
(SEM)  as the concentration of PGE1 is increased. The [B] 50 of PGE1 in the case
of  [2-O-methyltyrosine]-oxytocin  amounted  to  5.1  X  10-10  M which  cor-
responds to a pD2' value of 9.29  i- 0.05  (SEM).
Similarly, the inhibition by PGE1 of the theophylline-induced  hydroosmotic
response is characterized  by a marked reduction of the maximal response from
0.78  +  0.04  (SEM)  to 0.10  4- 0.01  (sEM)  (Fig.  5  B).  In this case  the [B1 25 0 of
PGE1 was  found to be  5.4  X  10-10  M which  corresponds  to a pD2'  value of
9.27  0.07  (SEM).
The  dose-response  curves  of  theophylline  and  of  [2-O-methyltyrosine]-
oxytocin  are  clearly  influenced  in a  similar  fashion by  PGE1;  however,  the
response  to  oxytocin  appears  at first  glance  to  be  influenced  differently  by
PGE1 . The results of a representative  experiment  are  illustrated  in Fig. 5 C.
When PGE1 was studied in the presence  of oxytocin, an agonist that can evoke
the  maximum response  of which  the  bladder  is  capable,  the dose-response
curve  of the  hormone was  shifted  to  the right  along  the log-dose  axis  ulti-
mately  with a  diminution  in the maximal  response  averaging  0.77  i  0.10.
Both the shift of the dose-response  curves  and the PGE-induced  diminution
of the maximal response to oxytocin exhibited considerable variation. Finally,
we compared the effect of PGE1 on the synergistic response of the combination
of cyclic AMP and theophylline  as well  as on the synergistic  response of the
combination  of oxytocin and theophylline.  PGE1 was employed at a concen-
tration  of  2.9  X  10- 7 M  which  is  sufficiently  high to inhibit  completely  the
responses of the bladder to a low concentration  of either oxytocin or theophyl-
line. As noted above, PGE1 has little effect on the action of exogenous dibutyryl
cyclic  AMP  on  the  bladder.  Whereas  the  near  maximal  hydroosmotic
4 It  should be noted that maximal concentrations  of exogenous dibutyryl  cyclic AMP gave a maxi-
mal  hydroosmotic  response  somewhat  lower than  that obtained  with  maximal  concentrations  of
deamino-oxytocin.
261THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  VOLUME  56  - 1970
response  evoked  by  the oxytocin-theophylline  combination  was  reduced  by
PGE1 to almost basal  levels,  PGEI reduced  the response  to the cyclic  AMP-
theophylline combination  only minimally  (Fig. 6).
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FIGURE 5.  Inhibitory  action  of prostaglandin  (PGEI)  on the hydroosmotic  response  of
the  toad  bladder  to  the  following  agonists:  (A)  [2-O-methyltyrosine]-oxytocin,  (B)
theophylline,  (C)  oxytocin,  (D)  N6-2'-O-dibutyryl  cyclic  3',5'-adenosine  monophos-
phate. Log dose-response  of agonist A alone (o-o)  and in the presence of increasing
concentrations of PGEI,  B'  (2.9  X  10-10  M,  o-----o; 1.4  X  10- 9M,  m-----; 2.9  X  10-9M,
*-----  ; 2.9  X  10
- 7 M,  A----A).  The maximal  antagonism by PGEI is given by h,'  and
the  concentration  of PGEI  associated  with  half-maximal  antagonism  is given  by the
[B']60 value.  Each point  represents  the  average of six or  more  experiments.  The dose-
response  curves  of  the  agonists  in  the  presence  of  PGE1 have  been  normalized  with
respect to  the response  curve for the agonist alone.  The per cent maximal hydroosmotic
response  reached  with  saturating concentrations  of these agonists,  E/E,,  has  been
determined  in  separate  experiments  by  direct  comparison  with  deamino-oxytocin  in
contralateral  hemibladders.  Standard  errors  (SEM)  are given for  the responses  obtained
with  the highest concentrations  of agonists  tested.
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FIGURE  6.  Effect  of prostaglandin  (PGE1)  on  (A)  the  response  of the  bladder  to  a
theophylline-cyclic  AMP  combination  (THEO-AMP)  and on  (B)  the response  of the
bladder  to a theophylline-oxytocin  combination  (THEO-OXY).  (A)  Initially  two sets
of hemibladders were kept for 30 min in plain Ringer fluid  (control); during the follow-
ing  30 min period one set of hemibladders  was exposed  to  2.5  X  10- 3 M AMP  and the
contralateral  set of hemibladders was exposed to 4  X  10-3 M  THEO.  For the last 30 min
interval  one  of the  two  sets of hemibladders was  exposed  to  the combination  of 2.5  X
10-3 M AMP  and 4  X  10-3 M THEO,  while  the  contralateral  set  was  exposed  to  a
medium  containing  2.5  X  10-3 M AMP, 4  X  10-3 M THEO, and  2.9  X  10- 7M PGE1.
(B)  The experimental  procedure  was  identical  to that used  in  (A); however,  in these
experiments  1 X  10- 9M OXY  was  substituted for AMP. The graph depicts  the  mean
and standard error of the mean (sEM)  of values obtained in eight experiments.
DISCUSSION
The  water  permeability  response  of  the  toad  urinary  bladder  is  rather
specific  in  that  only  three  types  of  compounds  have  to  date  been  found
capable  of eliciting this effect reversibly: neurohypophyseal  hormones  (9,  23,
41),  methylxanthines,  and  cyclic AMP  (33).  There  is considerable  evidence
that cyclic AMP is involved in the mediation of the action of neurohypophy-
seal  hormones  as well  as of theophylline  (32).  Both the hormones and theo-
phylline raise the intracellular level of cyclic AMP; the former by stimulating
the adenyl cyclase  system, the latter by inhibiting cyclic nucleotide phospho-
diesterase,  the enzyme  which  inactivates  cyclic  AMP  by  hydrolysis  to  give
5'-AMP  (13,  21).
In  the present  study we are  exploring  the interplay  of neurohypophyseal
hormonal peptides,  theophylline,  and prostaglandin E1 (PGE 1)-all  of which
affect the intracellular level of cyclic AMP.  Specifically,  we are investigating
whether  each increment  of adenyl cyclase  activity can be translated  into an
increment  of hydroosmotic  activity,  or  whether  steps  subsequent  to  adenyl
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cyclase activation are limiting in the over-all response of the tissue to hormone.
In this context  we studied a series of neurohypophyseal  peptides  (oxytocin,
[2-O-methyltyrosine]-oxytocin,  and  [2-O-ethyltyrosine]-oxytocin)  possessing
different intrinsic  ("catalytic")  activities with respect to their ability to evoke
the  hydroosmotic  response.  The  two  latter  compounds  had  already  been
shown to exhibit inhibitory properties or decreased  maximal effects in several
other hormone-sensitive  tissues  (37); moreover,  in an earlier investigation  we
had  observed  a  diminution  in  the  intrinsic  hydroosmotic  activity  of [2-0-
methyltyrosine]-oxytocin  on the toad  bladder  (18).
We noted (18)  that the replacement of the hydroxy radical in tyrosine by a
methoxy  moiety  results  in  a decline  in the  maximal hydroosmotic  response
from  100%  to 88%. The replacement  of the  hydroxy  moiety  by  the  ethoxy
radical abolished  the response  completely,  a finding which could be due on
the one  hand to the inability of this analogue  to bind to the receptor at the
concentrations  used,  or,  on  the other hand,  to the inability  of the  hormone-
receptor complex to catalyze  a permeability  response. In the latter case [2-0-
ethyltyrosine]-oxytocin  should  competitively  inhibit the bladder  response  to
oxytocin and other active analogues.  We therefore  studied the effect of [2-0-
ethyltyrosine]-oxytocin  on  the  dose-response  relationship  of  oxytocin,  dea-
mino-oxytocin,  [8-arginine]-vasopressin,  [5-ornithine]-oxytocin,  and  [2-0-
methyltyrosine]-oxytocin,  a group  of agonists  which  vary  greatly  in  their
affinity constants for the receptor.  It was established  that [2-0-ethyltyrosine]-
oxytocin  was  an  equipotent  competitive  inhibitor  of  all  these  agonists  as
indicated  by the minimal variation in the pA2 value  (see Table II).
The fact that  the  binding  constant  of  [2-0-ethyltyrosine]-oxytocin  (indi-
cated by a pA2 =  6.83  0.11  (SEM))  is the same within the limits of experi-
mental error as that of [2-O-methyltyrosine]-oxytocin  (indicated  by a pD  =
7.09  4- 0.05  (sEM))-although  the maximal  hydroosmotic  activity  of  these
two  analogues  was  found  to  be  0  and  88%,  respectively-shows  that  the
structural  alteration  of the  tyrosine residue  resulted in  a selective  change  in
the catalytic  function of this hormonal principle.  Thus the intrinsic activities
of oxytocin,  [2-0-methyltyrosine]-oxytocin,  and  [2-O-ethyltyrosine]-oxytocin
decline progressively  resulting  in a functional  mutation of the hormone from
agonist to partial agonist to competitive  antagonist.
In this context it is of interest that the graded properties of partial agonism
shown  by [2-O-methyltyrosine]-oxytocin  and  [2-O-ethyltyrosine]-oxytocin  in
the toad bladder system have an exact parallel in the action of these peptides
as well as in the action of the corresponding  analogues  of [8-lysine]-vasopres-
sin, on the isolated rat uterus and on the isolated rattail artery  (38).
In addition to the above studies, we found that [4-leucine]-mesotocin  (36)-
an  analogue  of mesotocin  (1,  39)  in which the  glutamine residue in position
4  is  replaced  by a leucine  residue-did  not evoke  a hydroosmotic  response,
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but inhibited competitively the action of oxytocin.  In the light of this finding,
it would be of interest to investigate whether the analogue with an analogous
replacement  in  the  oxytocin  series,  namely  [4-leucine]-oxytocin  (14),  has
comparable  antagonistic properties in the hydroosmotic  assay.5
Thus,  [2-O-ethyltyrosine]-oxytocin  and  [4-leucine]-mesotocin  appear  to
bind  to  the  hormonal  receptor  but do  not evoke  the hydroosmotic  effect.
However,  the absence of a final effect  need not imply that the interaction  of
the peptide with its receptor  had not produced  an increase in the activity of
adenyl  cyclase because  cyclic AMP production  may be increased  above  the
basal  rate  and yet be  insufficient to  assure  the  minimum  intracellular  level
(threshold)  needed to trigger the event(s) leading to a hydroosmotic  response.
In  order  to  determine  whether  the  toad  bladder  exhibits  such a  threshold
phenomenon  (8,  6,  26  44)  we  studied  the  effect  of  [2-O-ethyltyrosine]-
oxytocin  on  the bladder  by using  theophylline  to  retard  the destruction  of
cyclic AMP and thereby to amplify any subthreshold  effects which the ana-
logue may have had on the adenyl cyclase system.  The fact that the relation-
ship  of  hydroosmotic  activity  to  theophylline  dosage  is  shifted  to  the  left
(Fig. 4)  by the influence of [2-0-ethyltyrosine]-oxytocin  shows that the latter
compound  can  act as a  synergist  of theophylline.  It  seems  likely that  this
synergism is a consequence of adenyl cyclase activation by [2-O-ethyltyrosine]-
oxytocin rather than a peptide-dependent increase of the effect of theophylline
on phosphodiesterase;  in the latter instance one would not expect the observed
increase  in  the  maximal response  of  the bladder  to  theophylline  following
addition  of the peptide  (Fig.  4).
In order to substantiate the idea that this synergism is a direct consequence
of  the  interaction  of  [2-O-ethyltyrosine]-oxytocin  with  the  same  receptor
responsible for adenyl cyclase activation by oxytocin, it was necessary to show
for both the  antagonistic  and  the  synergistic  actions  of [2-0-ethyltyrosine]-
oxytocin  identity  of  binding  constants,  a  criterion  indicative  of  receptor
identity. For this purpose we determined the affinity constant of the synergist
and referred  to the logarithm of this constant as pS2 . As an antagonist [2-0-
ethyltyrosine]-oxytocin proved to have an averagepA2 of 6.83  zt 0.11  (SEM),  a
value which closely  approximates  the pS2 value  of 7.00  4  0.05  (sEM)  found
for  its  synergistic  action.  These  results  support  the  contention  that  [2-0-
ethyltyrosine]-oxytocin-although  incapable  by  itself  at  concentrations  as
high  as  10-5  M of eliciting  a  hydroosmotic  response-stimulates  the  adenyl
cyclase enzyme  system above its basal rate of activity.  Moreover,  this experi-
ment suggests that low levels of adenyl cyclase stimulation  are not translated
into permeability  changes and, accordingly,  that the effector system,  i.e.  the
5 Note Added in Proof  It  has indeed  recently  been  reported  that this  analogue  competitively  in-
hibits  the  hydroosmotic  action  of  [8-arginine]-vasopressin  and  [8-arginine]-vasotocin  in  the toad
bladder  (Chiu,  P.J.S.  and  W.H. Sawyer.  1970). Amer. J.  Physiol. 218:838.
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hydroosmotic  permeability barrier  of the toad bladder epithelium,  exhibits  a
threshold with respect to cyclic AMP.
The  activities  of  adenyl  cyclase  and  phosphodiesterase  in  unstimulated
target tissues are balanced so that the level of cyclic AMP is maintained below
threshold;  this  may  be  physiologically  significant  in  preventing  fortuitous
hydroosmotic  responses to small fluctuations in enzyme  activity and, thereby,
serve  to keep  the  target  tissue  under  the  control  of  its  primary  hormonal
regulator.
It has recently become apparent that prostaglandins participate in a critical
way  in modulating  the action  of a number  of hormones  in  different  tissues
(11,  24). Butcher and Baird (12)  have shown that prostaglandin  E1 diminishes
the lipolytic effect of several hormones by lowering hormone-dependent  cyclic
AMP  levels  in isolated  fat cells  of the rat,  while  in  other  tissues  (hemidia-
phragm,  spleen,  kidney,  and  testis)  PGE1 alone  raises  cyclic  AMP  levels.
Others  (10,  34)  have  postulated  that prostaglandin  may function  as a feed-
back regulator on the cyclic AMP mechanism either by influencing the activity
of  adenyl  cyclase  or  of  phosphodiesterase.  We  therefore  reexamined  the
inhibitory properties  of PGE1 on the hydroosmotic  action  of neurophyophy-
seal  peptides,  theophylline,  and  cyclic  AMP  and  its  dibutyryl  derivative.
In  confirmation  of  the  observations  of  Orloff,  Handler,  and  Bergstr6m
(34),  we found PGE1 to be a potent inhibitor of neurohypophyseal  hormones
but not  of cyclic  AMP  or its  more potent  dibutyryl  derivative  (Fig.  5  D).
Under  the  experimental  conditions  employed  theophylline  was  likewise
inhibited by PGE1 . Contrary to the suggestion  (31) that PGE 1 competes with
vasopressin  for  a  common  receptor  site,  our  findings  indicated  that  PGE1
behaves  as  a  noncompetitive  inhibitor  of neurohypophyseal  hormones  and
theophylline.  The  noncompetitive  nature  of  this  inhibition  can  be  most
clearly  illustrated  with a partial  agonist  for which  a receptor  reserve  is  ex-
cluded. Hence  a stepwise elimination  of receptors will result in a correspond-
ing decline of the dose-response  curve. This is shown in Fig. 5 A in which the
maximal response of the bladder to the partial agonist, [2-0-methyltyrosine]-
oxytocin,  is progressively  depressed with increasing  doses of PGE1, a finding
which indicates that the inhibitory action  of PGE1 is insurmountable.  More-
over, the maximal  PGE1-induced  depressions  of the log dose-response  curves
were similar for [2-0-methyltyrosine]-oxytocin  and for theophylline (Fig. 5 B),
and  the affinity  constants  of PGE1 for the "inhibited"  receptor(s)  were  the
same within the limits  of error.
The inhibitory effect  of PGE1 on oxytocin  (Fig. 5  C) appears  at first sight
to be competitive because increasing concentrations of PGE1 cause apparently
parallel  shifts to higher concentrations of the oxytocin dose-response  curve-
suggesting that in the case of oxytocin  the  inhibitory action  of PGE1 may be
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FIGURE  7.  Interpretation  of the  relationship  between the  "second messenger"  (AMP)
and the  final  effector  response  (hydroosmosis)  of the  toad  urinary  bladder  to  neuro-
hypophyseal  peptides,  theophylline,  and  prostaglandin  El.  The  relation  between  the
level  of intracellular  cyclic  AMP  (ordinate),  and  the  theophylline-induced  inhibition
of cyclic  nucleotide phosphodiesterase  represented  in terms  of theophylline  concentra-
tion  (abscissa)  suggests that this hormone-sensitive  tissue  exhibits a subthreshold  and a
reserve  region with regard to the response to cyclic AMP. The coefficient of proportion-
ality  relating  intracellular  [AMP]  and  [Theophylline]  is  the  adenyl  cyclase  activity.
Thus the  slope  of the  regression  of [AMP]  on .Theophylline]  (--l)  will  increase
with adenyl  cyclase  stimulation  by neurohypophyseal  peptides  (--  )  and  decrease
with adenyl cyclase inhibition by PGE1 (o-o).  The quantitative relationships shown
in the subthreshold  and reserve regions are derived by extrapolation from experimental
data obtained  in the  effect region  (Figs.  4 and  5B).
surmountable.  But,  unlike the action of a competitive inhibitor,  the action of
PGE1 exhibits a saturation phenomenon  (i.e. there is a limit to the degree to
which PGE1 can  displace  the oxytocin dose-response  curve  to the right [Fig.
5  C]).  This  observation,  together  with  the  evidence  that  oxytocin  and
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[2-0-methyltyrosine]-oxytocin  act  on  the  same  receptors,6 suggests  that the
inhibition of oxytocin by PGEI is also noncompetitive.
Assuming,  therefore,  that  PGE1 is  indeed  a  noncompetitive  inhibitor  of
oxytocin,  the fact that maximal oxytocin concentrations  in combination with
maximal PGE1 concentrations evoke an almost full hydroosmotic response can
be  explained  if  oxytocin  at  saturating  concentrations  generates  a stimulus
considerably in excess of that required for eliciting the maximal hydroosmotic
response. These results are consistent with the view that oxytocin  and certain
other neurohypophyseal  peptides are  capable  of evoking  a  maximal  hydro-
osmotic response in the toad bladder with only partial occupation  of the total
number  of  receptors  available-a  phenomenon  referred  to  as  "receptor
reserve"  (6,  30,  42). Peptides  which exhibit this  phenomenon  evidently can
produce  levels  of intracellular  cyclic  AMP  well  above  that  required  for  a
maximal response.  Supramaximal levels  of intracellular  cyclic AMP can also
be  obtained  with  certain  neurohypophyseal  peptides  which  are  themselves
incapable of eliciting  a hydroosmotic  response provided that the degradation
of the intracellular  cyclic AMP formed is sufficiently retarded. Most probably
this  situation  was  encountered  in  the case  of  the  synergism  between  [2-0-
ethyltyrosine]-oxytocin  and  theophylline  (Fig.  4).  In the present  study both
processes,  synergism  and  noncompetitive  antagonism,  appear  to  modulate
the  stimulus  formation  rather  than the  final  effector  process.  The foregoing
analysis  and  experimental  findings  are  presented  schematically  in Fig.  7.
The last  question  investigated  was  whether  PGE1 acts directly  on  adenyl
cyclase,  phosphodiesterase,  both,  or  neither.  As can  be  seen  from Fig.  5  A
and B,  PGE1 possesses  an identical  binding constant for its inhibitory  actions
on the response to  [2-0-methyltyrosine]-oxytocin  and  theophylline,  findings
which suggest  that  both inhibitory  effects  are  probably  exerted  through  an
action of PGE, at the same receptor. This receptor must be functionally  con-
nected  with  adenyl  cyclase  because  both  exogenous  cyclic  AMP  and  its
dibutyryl  derivative  are  essentially  unaffected  by  PGE1 . To  obtain  direct
evidence  on  the question  of whether  or not  PGE1 also acts  on the  phospho-
diesterase  system, we compared the effect of PGE1 on a theophylline-oxytocin
combination  vs.  a theophylline-exogenous  cyclic AMP combination  (Fig.  6).
The synergistic  effect  of the  theophylline-cyclic  AMP  combination,  which is
independent  of  adenyl cyclase  activity,  but dependent  upon  3', 5'-phospho-
diesterase  activity,  was only minimally  affected by the presence  of PGE  .
In  conclusion,  our studies of the graded catalytic  activities of oxytocin and
selected  analogues  have  shown  that the  toad urinary  bladder-with  respect
to its hydroosmotic reactivity-exhibits  threshold and receptor reserve pheno-
mena.  Thus the  stimulus-effect  relationship  in  the mechanism  of  action  of
I Equivalent pA2 values for the competition  of [2-O-ethyltyrosine]-oxytocin  with oxytocin and with
[2-O-methyltyrosine]-oxytocin  (Table II) suggest that all three compounds act at the same receptor.
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neurohypophyseal  hormones  is  discontinuous  inasmuch  as  an  increasing
stimulus in the subthreshold range  evokes no response at all, and an increasing
stimulus in the receptor-reserve  range evokes no further increase in response.
Therefore,  the intrinsic activity of a hormonal peptide is better defined by its
effect on the catalytic  activity  of adenyl cyclase,  than by its  final  biological
effect  on  membrane  permeability.
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